If the drug doesn’t shrink your belly fat by at least 8%, it won’t make your fat look healthier on scans — you have to respond to the drug for this benefit.
Scientific Claim
In people living with HIV (PWH) with central adiposity, tesamorelin treatment for 26 weeks does not improve fat density in non-responders, as placebo-treated participants showed no significant change in VAT or SAT density.
Original Statement
“Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: +6.2 (8.7) HU tesamorelin, +0.3 (4.2) HU placebo, P < 0.0001; SAT: +4.0 (8.7) HU tesamorelin, +0.3 (4.8) HU placebo, P < 0.0001].”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim is directly supported by the placebo group data showing no significant change. Language is precise and avoids overgeneralization.
Evidence from Studies
Supporting (0)
Contradicting (1)
Tesamorelin improves fat quality independent of changes in fat quantity
The study found that tesamorelin improved fat quality in people who lost belly fat, but it didn’t even look at people who didn’t lose fat — so we can’t say whether it helped or didn’t help them.